(NASDAQ: VERU) Veru's forecast annual revenue growth rate of 16.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Veru's revenue in 2025 is $6,656,522.On average, 1 Wall Street analysts forecast VERU's revenue for 2028 to be $732,519,600, with the lowest VERU revenue forecast at $732,519,600, and the highest VERU revenue forecast at $732,519,600. On average, 1 Wall Street analysts forecast VERU's revenue for 2029 to be $1,831,299,000, with the lowest VERU revenue forecast at $1,831,299,000, and the highest VERU revenue forecast at $1,831,299,000.
In 2030, VERU is forecast to generate $3,296,338,200 in revenue, with the lowest revenue forecast at $3,296,338,200 and the highest revenue forecast at $3,296,338,200.